Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab rechallenge plus irinotecan- or oxaliplatin-based chemotherapy in RAS wild-type advanced colorectal cancer
2016-003644-37Phase 2Completed
- Sponsor
- HeCOG
- Start
- Apr 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of panitumumab in colorectal cancer (CRC), metastatic colorectal adenocarcinoma (mCRC), sponsored by HeCOG. Started Apr 2017; status: completed.
02
Drugs
panitumumab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2016-003644-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003644-37.